Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | PDE5A | O76074 | 12/20 | 0.53 |
| ▸ | GUCY1A1 | Q02108 | 6/20 | 0.49 |
| ▸ | GUCY1B1 | Q02153 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15111651 | 0.89 | PDE5A (0.55) | ADORA3KCNH2PDE5A | |
| SCHEMBL27962849 | 0.87 | ADORA3 (0.48) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL15111729 | 0.85 | ADORA3 (0.62) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6216180 | 0.85 | ADORA3 (0.55) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6219289 | 0.85 | ADORA3 (0.54) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6218458 | 0.84 | ADORA3 (0.61) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL6218288 | 0.84 | ADORA3 (0.55) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL15111839 | 0.83 | ADORA3 (0.60) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174342 | 0.83 | ADORA3 (0.54) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL974087 | 0.81 | ADORA3 (0.56) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2802580-B1 | SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER IP GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9133191-B2 | Substituted triazine derivatives and use thereof as stimulators of soluble guanylate cyclase | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133191-B2 | Substituted triazine derivatives and use thereof as stimulators of soluble guanylate cyclase | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133191-B2 | Substituted triazine derivatives and use thereof as stimulators of soluble guanylate cyclase | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20150094308-A1 | SUBSTITUTED TRIAZINE DERIVATIVES AND USE THEREOF AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-02 | — | — | US | disclosed |
| US-20150094308-A1 | SUBSTITUTED TRIAZINE DERIVATIVES AND USE THEREOF AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-02 | — | — | US | disclosed |
| US-20150094308-A1 | SUBSTITUTED TRIAZINE DERIVATIVES AND USE THEREOF AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094308-A1 | SUBSTITUTED TRIAZINE DERIVATIVES AND USE THEREOF AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | GUCY1A2, GUCY1B2, GUCY1B1 | ADORA3 394/4885KCNH2 1202/4885PDE5A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.